High-dose therapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: An alternative to bone marrow purging

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Throughout a 4-year period, we reinfused autologous peripheral stem cells rather than purged autologous bone marrow following high-dose therapy to 57 patients with relapsed lymphoma and bone marrow metastases. Approximately 7 x 108 circulating mononuclear cells/kg patient weight were collected for each patient with 6-19 4-h apheresis procedures while hemopoiesis was unperturbed. Following collection, the cells were cryopreserved. Administration of high-dose therapy, which included either combination chemotherapy or combination chemotherapy plus total body irradiation, was followed by i.v. administration of the thawed autologous stem cells. The rate of hemopoietic recovery varied with the specific high-dose therapy administered. Sixty-two percent of 50 evaluable patients had a clinical complete response. The actuarial event-free survival for these patients 4 years after transplantation was 30%, and the projected survival at 4 years was 51%. Patients with relapsed lymphoma and bone marrow metastases who receive high dose therapy followed by peripheral stem cell transplantation can experience long-term event-free survival. Whether similar patients would fare as well with the same high-dose therapy followed by a purged autologous bone martow transplantation would require a randomized prospective study.

Original languageEnglish (US)
Pages (from-to)1013-1016
Number of pages4
JournalExperimental Hematology
Volume19
Issue number10
StatePublished - Oct 22 1991

Fingerprint

Bone Marrow Purging
Peripheral Blood Stem Cell Transplantation
Lymphoma
Bone Marrow
Neoplasm Metastasis
Combination Drug Therapy
Therapeutics
Disease-Free Survival
Blood Component Removal
Bone Transplantation
Autologous Transplantation
Whole-Body Irradiation
Stem Cells
Transplantation
Prospective Studies
Weights and Measures
Survival

Keywords

  • high-dose therapy
  • lymphoma
  • peripheral stem cells

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Genetics
  • Cell Biology
  • Cancer Research

Cite this

@article{79083042a2de4aad88528a3ae685be48,
title = "High-dose therapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: An alternative to bone marrow purging",
abstract = "Throughout a 4-year period, we reinfused autologous peripheral stem cells rather than purged autologous bone marrow following high-dose therapy to 57 patients with relapsed lymphoma and bone marrow metastases. Approximately 7 x 108 circulating mononuclear cells/kg patient weight were collected for each patient with 6-19 4-h apheresis procedures while hemopoiesis was unperturbed. Following collection, the cells were cryopreserved. Administration of high-dose therapy, which included either combination chemotherapy or combination chemotherapy plus total body irradiation, was followed by i.v. administration of the thawed autologous stem cells. The rate of hemopoietic recovery varied with the specific high-dose therapy administered. Sixty-two percent of 50 evaluable patients had a clinical complete response. The actuarial event-free survival for these patients 4 years after transplantation was 30{\%}, and the projected survival at 4 years was 51{\%}. Patients with relapsed lymphoma and bone marrow metastases who receive high dose therapy followed by peripheral stem cell transplantation can experience long-term event-free survival. Whether similar patients would fare as well with the same high-dose therapy followed by a purged autologous bone martow transplantation would require a randomized prospective study.",
keywords = "high-dose therapy, lymphoma, peripheral stem cells",
author = "A. Kessinger and Vose, {Julie Marie} and Bierman, {Philip Jay} and Armitage, {James Olen}",
year = "1991",
month = "10",
day = "22",
language = "English (US)",
volume = "19",
pages = "1013--1016",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - High-dose therapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma

T2 - An alternative to bone marrow purging

AU - Kessinger, A.

AU - Vose, Julie Marie

AU - Bierman, Philip Jay

AU - Armitage, James Olen

PY - 1991/10/22

Y1 - 1991/10/22

N2 - Throughout a 4-year period, we reinfused autologous peripheral stem cells rather than purged autologous bone marrow following high-dose therapy to 57 patients with relapsed lymphoma and bone marrow metastases. Approximately 7 x 108 circulating mononuclear cells/kg patient weight were collected for each patient with 6-19 4-h apheresis procedures while hemopoiesis was unperturbed. Following collection, the cells were cryopreserved. Administration of high-dose therapy, which included either combination chemotherapy or combination chemotherapy plus total body irradiation, was followed by i.v. administration of the thawed autologous stem cells. The rate of hemopoietic recovery varied with the specific high-dose therapy administered. Sixty-two percent of 50 evaluable patients had a clinical complete response. The actuarial event-free survival for these patients 4 years after transplantation was 30%, and the projected survival at 4 years was 51%. Patients with relapsed lymphoma and bone marrow metastases who receive high dose therapy followed by peripheral stem cell transplantation can experience long-term event-free survival. Whether similar patients would fare as well with the same high-dose therapy followed by a purged autologous bone martow transplantation would require a randomized prospective study.

AB - Throughout a 4-year period, we reinfused autologous peripheral stem cells rather than purged autologous bone marrow following high-dose therapy to 57 patients with relapsed lymphoma and bone marrow metastases. Approximately 7 x 108 circulating mononuclear cells/kg patient weight were collected for each patient with 6-19 4-h apheresis procedures while hemopoiesis was unperturbed. Following collection, the cells were cryopreserved. Administration of high-dose therapy, which included either combination chemotherapy or combination chemotherapy plus total body irradiation, was followed by i.v. administration of the thawed autologous stem cells. The rate of hemopoietic recovery varied with the specific high-dose therapy administered. Sixty-two percent of 50 evaluable patients had a clinical complete response. The actuarial event-free survival for these patients 4 years after transplantation was 30%, and the projected survival at 4 years was 51%. Patients with relapsed lymphoma and bone marrow metastases who receive high dose therapy followed by peripheral stem cell transplantation can experience long-term event-free survival. Whether similar patients would fare as well with the same high-dose therapy followed by a purged autologous bone martow transplantation would require a randomized prospective study.

KW - high-dose therapy

KW - lymphoma

KW - peripheral stem cells

UR - http://www.scopus.com/inward/record.url?scp=0026094766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026094766&partnerID=8YFLogxK

M3 - Article

C2 - 1680733

AN - SCOPUS:0026094766

VL - 19

SP - 1013

EP - 1016

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 10

ER -